The effects of infliximab therapy on the serum proteome of rheumatoid arthritis patients

Table 1 Patients and their classification according to responses based on disease activity score and C-reactive protein level after 12 weeks of infliximab treatment

Patient ID number	DAS28		Δ DAS	EULAR DAS28 response^a	CRP mg/L		Δ CRP
	Baseline (T0)	Week 12 (T12)			Baseline (T0)	Week 12 (T12)
10611	5.7	5.2	0.5	NR	4.3	29.1	-24.8
10612	6.2	7.6	-1.4	NR	37.4	139.0	-101.6
10613	5.8	3.6	2.3	R	13.0	9.0	4.0
10616	6.8	3.9	2.9	R	46.0	1.0	45.0
10618	6.3	3.8	2.5	NR^b	43.3	52.0	-8.7
10619	3.2	3.7	-0.5	NR	6.0	8.0	-2.0
10620	4.9	5.1	-0.2	NR	17.1	2.3	14.8
10621	3.8	4.2	-0.5	NR	68.0	68.0	0.0
10622	6.0	6.6	-0.6	NR	24.4	86.2	-61.8
10623	6.2	4.5	1.7	R	51.3	12.4	38.9

^aPatients were deemed to be European League Against Rheumatism (EULAR) responders (Rs) if they had a reduction in DAS28 of greater than or equal to 1.2; all others were considered non-responders (NRs) for analysis purposes. ^bSubject 10618 achieved a reduction in DAS28 of 2.5, but C-reactive protein (CRP) level increased at T12; thus, to ensure homogeneity in the R group, we excluded this patient from the group. DAS, disease activity score; DAS28, disease activity score using 28 joint counts.

ISSN: 1478-6362